

12/12/2017

To,  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001

Dear Sir,

**Sub: Un-audited Financial Results along with Limited Review Report of the Statutory Auditors for the Quarter and Half year ended 30<sup>th</sup> September, 2017.**

**BSE Code: 531210**

Pursuant to regulation 30 & 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to enclose herewith Un-audited Financial Results of the Company for the Quarter and Half year ended 30<sup>th</sup> September, 2017 as approved by Audit Committee and thereafter by the Board of Directors at its meeting held today.

The meeting of Board of Directors of the Company commenced at 1.30 p.m. and concluded at 3.15 p.m.

We also enclosed herewith Limited Review Report of the Statutory Auditors of the Company in respect of the said results.

We request you take the same on your record.

Thanking you,

Yours faithfully,  
FOR COLINZ LABORATORIES LTD

  
DR. MANI L.S.  
MANAGING DIRECTOR  
DIN: 00825886





**VORA & ASSOCIATES**  
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS  
31, NEW MARINE LINES  
MUMBAI - 400 020. INDIA

022-2200 5933 - 2200 5934  
022-2206 3289 - 6615 5599  
www.cavoras.com  
office@cavoras.com  
cavoras@gmail.com

Ref.: MA: 17: CSL 968

Review report to:  
The Board of Directors,  
**Colinz laboratories Limited,**  
A-101, Pratik Indl. Estate,  
Mulund Goregaon Link Road,  
Mumbai - 400 078.

**Reg.: THE LIMITED REVIEW REPORT FOR COMPANIES**  
**ANNEXURE V TO REGULATION 33**

**CERTIFICATE**

We have reviewed the accompanying statement of unaudited financial results of **COLINZ LABORATORIES LIMITED** for the quarter and half year ended 30<sup>th</sup> September, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Statements by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The unaudited financial results for the quarter and half year ended 30<sup>th</sup> September 2016 included in the Statement, are based on the previously issued results of the Company prepared in accordance with the Accounting Standards as per Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 ("previous GAAP"). Those unaudited financial results prepared under previous GAAP were received by the predecessor auditors, whose limited review report expressed an unmodified conclusion on those unaudited financial results. Management has adjusted those unaudited financial results for the differences in the accounting principles adopted by the Company on transition to Indian Accounting Standard ("Ind AS") and presented a reconciliation for the same, which has been approved by the Company's Board of Directors but have not been subjected to review.





**VORA & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

101-103, REWA CHAMBERS  
31, NEW MARINE LINES  
MUMBAI - 400 020. INDIA


☎ 022-2200 5933 - 2200 5934  
022-2206 3289 - 6615 5599

🌐 [www.cavoras.com](http://www.cavoras.com)

✉ [office@cavoras.com](mailto:office@cavoras.com)  
[cavoras@gmail.com](mailto:cavoras@gmail.com)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES  
CHARTERED ACCOUNTANTS  
(ICAI Firm Reg. No.: 111612W)

  
RONAK A. RAMBHIA  
PARTNER  
(Membership No. 140371)



PLACE: MUMBAI

DATED: 12 DEC 2017



## COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED : 30th September, 2017

"(Rs. In Lakhs)"

S. No.	Particulars	Un - audited					Audited
		Quarter ended			Six Month Ended		YEAR ENDED
		30-Sep-2017	30-Jun-2017	30-Sep-2016	30-Sep-2017	30-Sep-2016	31-Mar-17
<b>PART - I</b>							
1	(a) Revenue from Operation	227.70	185.95	208.38	413.65	447.15	804.70
3	(b) Other Income	1.90	2.24	7.05	4.14	9.10	14.09
3	<b>Total Income from Operation</b>	<b>229.60</b>	<b>188.19</b>	<b>215.43</b>	<b>417.79</b>	<b>456.25</b>	<b>818.79</b>
4	<b>Expenses</b>						
(a)	Cost Of Material Consumed	29.02	42.74	67.48	71.77	97.25	129.55
(b)	Purchase of Stock in Trade	30.65	5.73	29.10	36.38	55.70	158.04
(c)	Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	47.03	11.61	(18.55)	58.64	24.60	6.83
d)	Excise Duty	0.00	7.64	13.16	7.64	27.53	41.04
(e)	Employee Benefit Expenses	77.56	78.27	74.44	155.82	148.20	291.36
(f)	Finance Cost	1.92	2.15	2.53	4.07	5.24	11.79
(g)	Depreciation & Amortisation Expenses	5.53	5.53	6.63	11.06	13.25	26.50
(h)	Other Expenses	31.91	35.58	32.34	67.49	72.40	136.95
	<b>Total Expenses</b>	<b>223.62</b>	<b>189.25</b>	<b>207.13</b>	<b>412.87</b>	<b>444.17</b>	<b>802.06</b>
5	<b>Profit /(Loss) Before exceptional items and tax ( 3-4)</b>	<b>5.98</b>	<b>(1.06)</b>	<b>8.30</b>	<b>4.92</b>	<b>12.08</b>	<b>16.73</b>
6	Exceptional items		-				
7	<b>Profit /(Loss) before tax (5-6)</b>	<b>5.98</b>	<b>(1.06)</b>	<b>8.30</b>	<b>4.92</b>	<b>12.08</b>	<b>16.73</b>
8	Tax Expenses ( Provision for Taxation ) Current tax	1.20	-	0.60	1.20	1.20	2.34
i)	Current Tax						(3.70)
ii)	Deffered Tax	4.78	(1.06)	7.70	3.72	10.88	18.09
9	<b>Profit /(Loss) for the period from continuing operations(7-8)</b>	<b>4.78</b>	<b>(1.06)</b>	<b>7.70</b>	<b>3.72</b>	<b>10.88</b>	<b>18.09</b>
10	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
11	Tax expenses of discontinued operations	-	-	-	-	-	-
12	<b>Profit /(Loss) for the period</b>	<b>4.78</b>	<b>(1.06)</b>	<b>7.70</b>	<b>3.72</b>	<b>10.88</b>	<b>18.09</b>
13	<b>Other Comprehensive Income ( Net of Tax)</b>						
A)	Item that will not be reclassified to Profit or Loss Account						
i)	Change in fair value of investment in Equity Instruments	3.34	4.09	-	7.43	-	-
ii)	Income tax on above	-	-	-	-	-	-
14	<b>Total Comprehensive Income for the period (12+13) Comprising Profit/(Loss) and Other Comprehensive Income for the Period</b>	<b>4.78</b>	<b>(1.06)</b>	<b>7.70</b>	<b>11.15</b>	<b>10.88</b>	<b>18.09</b>



**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

Corp. Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, P. Box No. 17339 Mumbai - 400 078, INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel : +91-22-2566 8002 / 8003 Fax : +91-22-2566 8006

<b>STATEMENT OF ASSETS AND LIABILITIES</b>			
Particulars		30-Sep-2017	31-Mar-17
<b>Non-Current Assets</b>			
a) Property, Plants & Equipment		252.25	263.30
b) Capital Work-in progress		-	-
c) Intangible Assets		-	-
d) Financial Assets			
i) Investments		42.55	33.13
ii) Loans		-	-
iii) Other Financial Assets		-	-
e) Other Non Current Assets		126.99	127.93
<b>Total Non-Current Assets</b>		<b>421.79</b>	<b>424.36</b>
<b>Current Assets</b>			
a) Inventories		155.73	216.05
b) Financial Assets			
i) Trade Receivables		201.21	146.74
ii) Cash & Cash Equivalents		129.33	125.78
iii) Other Bank Balances		20.66	37.62
iv) Other Financial Assets		-	-
c) Other Current Assets		6.10	8.61
<b>Total Current Assets</b>		<b>513.03</b>	<b>534.80</b>
<b>TOTAL ASSETS</b>		<b>934.82</b>	<b>959.16</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
a) Equity Share Capital		354.41	354.41
b) Other Equity		302.63	289.50
<b>Total Equity</b>		<b>657.04</b>	<b>643.91</b>
<b>Liabilities</b>			
<b>Non-Current Liabilities</b>			
a) Financial Liabilities		-	-
i) Borrowings		85.28	135.37
b) Deferred Tax Liabilities ( Net)		41.22	41.22
c) Other Non Current Liabilities		0.96	0.88
<b>Total Non-Current Liabilities</b>		<b>127.46</b>	<b>177.47</b>
<b>Current Liabilities</b>			
a) Financial Liabilities			
i) Borrowings		-	-
ii) Trade Payables		62.43	45.15
iii) Other Financial Liabilities		-	-
b) Other Current Liabilities		87.89	92.63
c) Current Tax Liabilities (Net)		-	-
<b>Total Current Liabilities</b>		<b>150.32</b>	<b>137.78</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>934.82</b>	<b>959.16</b>



**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



**NOTES :-**

- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 12th Dec, 2017 Statutory Auditors of the Company have carried out a Limited Review of the Results and issued an unqualified report.
- 2) The Company has adopted IND-AS from 1-4-2017 and accordingly the Financial Results are prepared in accordance with the principles stated therein.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment as defined by IND -AS.
- 4) The reconciliation of net profit as reported under previous Generally Accepted Accounting Principals ( Previous GAAP) and as per IND-AS for the half year ended 30th September, 2017 is given below:

Net Profit as per OLD INDIAN GAAP	3.72	
(+)/(-) Impact of implementation of IND-AS		
Increase in fair value of Investments	7.43	-
Net Profit as per NEW GAAP	11.15	-

- 5) Previous have been regrouped/ rearranged / reclassified, wherever necessary.

MUMBAI.  
12th Dec, 2017.

For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**  
CIN NO : L24200MH1986PLC041128

  
**Dr. MANI L.S.**  
(Managing Director.)  
(DIN NO : 00825886)



**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

**Corp.Off.:** A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006